DiaMedica reports Q1 net loss $7.7M; preeclampsia Phase 2 topline data expected June-July 2025

DiaMedica Therapeutics Inc.

Net loss $7.7M ($0.18/sh) vs $5.2M ($0.14) in Q1 2024; R&D expense rose to $5.7M on trial expansion.
Cash $37.3M as of Mar 31, 2025 (down from $44.1M Dec 2024); runway into Q3 2026.
Phase 2 preeclampsia Part 1A topline results expected between 2H June and 1H July 2025; KOL event May 28.
ReMEDy2 stroke trial enrollment progressing; interim analysis on first 200 patients expected H1 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.